Process for the preparation of atorvastatin and intermediates
    1.
    发明申请
    Process for the preparation of atorvastatin and intermediates 失效
    制备阿托伐他汀和中间体的方法

    公开(公告)号:US20090131683A1

    公开(公告)日:2009-05-21

    申请号:US12222690

    申请日:2008-08-14

    IPC分类号: C07D207/333

    CPC分类号: C07D207/34

    摘要: A process is provided for preparing (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, R-substituted ester 9 comprising: (a) reacting the aldehyde 1 with the enolate form of (S)-2-hydroxy-1,2,2-triphenylethyl acetate substituent in a chelating co-solvent; (b) hydrolysis of (R,S)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-3-hydroxy-1-pentanoic acid, (S)-2-hydroxy-1,2,2-triphenylethyl ester (2a and 2b) using a base, preferably an alkali metal base, preferably in a solvent to form the carboxylic acid 7; (c) treating the acid 7 with a chiral base to form a salt and purifying the salt to obtain enantiomerically enriched (R)-7 chiral base salt; (d) alkylation of the (R)-7 chiral base salt or the free base derived from (R)-7, forming (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, R-substituted ester 9 and atorvastatin calcium 6, wherein R is a C1 to C6 alkyl, C6 to C9 aryl or C7 to C10 aralkyl.

    摘要翻译: 提供了制备(R)-5- [2-(4-氟苯基)-5-(1-甲基乙基)-3-苯基-4 - [(苯基氨基)羰基] -1H-吡咯-1-基] -5-羟基-3-氧代-1-庚酸,R-取代的酯9,其包含:(a)使醛1与烯醇化形式的(S)-2-羟基-1,2,2-三苯基乙基乙酸酯取代基 在螯合助溶剂中; (b)(R,S)-5- [2-(4-氟苯基)-5-(1-甲基乙基)-3-苯基-4 - [(苯基氨基)羰基] -1H-吡咯-1-基 ] -3-羟基-1-戊酸,(S)-2-羟基-1,2,2-三苯基乙酯(2a和2b),使用碱,优选碱金属碱,优选在溶剂中形成羧酸 酸7; (c)用手性碱处理酸7以形成盐并纯化该盐以获得对映体富集的(R)-7手性碱盐; (d)(R)-7手性碱盐或衍生自(R)-7的游离碱的烷基化,形成(R)-5- [2-(4-氟苯基)-5-(1-甲基乙基) - 3-苯基-4 - [(苯基氨基)羰基] -1H-吡咯-1-基] -5-羟基-3-氧代-1-庚酸,R-取代的酯9和阿托伐他汀钙6,其中R是C1 C6烷基,C6〜C9芳基或C7〜C10芳烷基。

    Process for the preparation of Atorvastatin and intermediates
    2.
    发明授权
    Process for the preparation of Atorvastatin and intermediates 失效
    阿托伐他汀和中间体的制备方法

    公开(公告)号:US07112604B2

    公开(公告)日:2006-09-26

    申请号:US11099624

    申请日:2005-04-06

    IPC分类号: A61K31/4025 C07D207/327

    CPC分类号: C07D207/34

    摘要: A process is provided for preparing (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, R-substituted ester 9 comprising: (a) reacting the aldehyde 1 with the enolate form of (S)-2-hydroxy-1,2,2-triphenylethyl acetate substituent in a chelating co-solvent; (b) hydrolysis of (R,S)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-3-hydroxy-1-pentanoic acid, (S)-2-hydroxy-1,2,2-triphenylethyl ester (2a and 2b) using a base, preferably an alkali metal base, preferably in a solvent to form the carboxylic acid 7; (c) treating the acid 7 with a chiral base to form a salt and purifying the salt to obtain enantiomerically enriched (R)-7 chiral base salt; (d) alkylation of the (R)-7 chiral base salt or the free base derived from (R)-7, forming (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, R-substituted ester 9 and atorvastatin calcium 6, wherein R is a C1 to C6 alkyl, C6 to C9 aryl or C7 to C10 aralkyl.

    摘要翻译: 提供了制备(R)-5- [2-(4-氟苯基)-5-(1-甲基乙基)-3-苯基-4 - [(苯基氨基)羰基] -1H-吡咯-1-基] -5-羟基-3-氧代-1-庚酸,R-取代的酯9,其包含:(a)使醛1与烯醇化形式的(S)-2-羟基-1,2,2-三苯基乙基乙酸酯取代基 在螯合助溶剂中; (b)(R,S)-5- [2-(4-氟苯基)-5-(1-甲基乙基)-3-苯基-4 - [(苯基氨基)羰基] -1H-吡咯-1-基 ] -3-羟基-1-戊酸,(S)-2-羟基-1,2,2-三苯基乙酯(2a和2b),使用碱,优选碱金属碱,优选在溶剂中形成羧酸 酸7; (c)用手性碱处理酸7以形成盐并纯化该盐,得到对映体富集的(R)-7手性碱盐; (d)(R)-7手性碱盐或衍生自(R)-7的游离碱的烷基化,形成(R)-5- [2-(4-氟苯基)-5-(1-甲基乙基) 3-苯基-4 - [(苯基氨基)羰基] -1H-吡咯-1-基] -5-羟基-3-氧代-1-庚酸,R-取代的酯9和阿托伐他汀钙6,其中R是C1 C6烷基,C6〜C9芳基或C7〜C10芳烷基。

    Process for the preparation of atorvastatin and intermediates
    3.
    发明授权
    Process for the preparation of atorvastatin and intermediates 失效
    制备阿托伐他汀和中间体的方法

    公开(公告)号:US07812179B2

    公开(公告)日:2010-10-12

    申请号:US12222690

    申请日:2008-08-14

    IPC分类号: C07D207/333

    CPC分类号: C07D207/34

    摘要: A process is provided for preparing (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, R-substituted ester 9 comprising: (a) reacting the aldehyde 1 with the enolate form of (S)-2-hydroxy-1,2,2-triphenylethyl acetate substituent in a chelating co-solvent; (b) hydrolysis of (R,S)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-3-hydroxy-1-pentanoic acid, (S)-2-hydroxy-1,2,2-triphenylethyl ester (2a and 2b) using a base, preferably an alkali metal base, preferably in a solvent to form the carboxylic acid 7; (c) treating the acid 7 with a chiral base to form a salt and purifying the salt to obtain enantiomerically enriched (R)-7 chiral base salt; (d) alkylation of the (R)-7 chiral base salt or the free base derived from (R)-7, forming (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, R-substituted ester 9 and atorvastatin calcium 6, wherein R is a C1 to C6 alkyl, C6 to C9 aryl or C7 to C10 aralkyl.

    摘要翻译: 提供了制备(R)-5- [2-(4-氟苯基)-5-(1-甲基乙基)-3-苯基-4 - [(苯基氨基)羰基] -1H-吡咯-1-基] -5-羟基-3-氧代-1-庚酸,R-取代的酯9,其包含:(a)使醛1与烯醇化形式的(S)-2-羟基-1,2,2-三苯基乙基乙酸酯取代基 在螯合助溶剂中; (b)(R,S)-5- [2-(4-氟苯基)-5-(1-甲基乙基)-3-苯基-4 - [(苯基氨基)羰基] -1H-吡咯-1-基 ] -3-羟基-1-戊酸,(S)-2-羟基-1,2,2-三苯基乙酯(2a和2b),使用碱,优选碱金属碱,优选在溶剂中形成羧酸 酸7; (c)用手性碱处理酸7以形成盐并纯化该盐以获得对映体富集的(R)-7手性碱盐; (d)(R)-7手性碱盐或衍生自(R)-7的游离碱的烷基化,形成(R)-5- [2-(4-氟苯基)-5-(1-甲基乙基) 3-苯基-4 - [(苯基氨基)羰基] -1H-吡咯-1-基] -5-羟基-3-氧代-1-庚酸,R-取代的酯9和阿托伐他汀钙6,其中R是C1 C6烷基,C6〜C9芳基或C7〜C10芳烷基。

    Process for the preparation of atorvastatin and intermediates
    4.
    发明授权
    Process for the preparation of atorvastatin and intermediates 失效
    制备阿托伐他汀和中间体的方法

    公开(公告)号:US07429613B2

    公开(公告)日:2008-09-30

    申请号:US11487500

    申请日:2006-07-17

    IPC分类号: A61K31/4025 C07D207/327

    CPC分类号: C07D207/34

    摘要: A process is provided for preparing (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, R-substituted ester 9 comprising: (a) reacting the aldehyde 1 with the enolate form of (S)-2-hydroxy-1,2,2-triphenylethyl acetate substituent in a chelating co-solvent; (b) hydrolysis of (R,S)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-3-hydroxy-1-pentanoic acid, (S)-2-hydroxy-1,2,2-triphenylethyl ester (2a and 2b) using a base, preferably an alkali metal base, preferably in a solvent to form the carboxylic acid 7; (c) treating the acid 7 with a chiral base to form a salt and purifying the salt to obtain enantiomerically enriched (R)-7 chiral base salt; (d) alkylation of the (R)-7 chiral base salt or the free base derived from (R)-7, forming (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, R-substituted ester 9 and atorvastatin calcium 6, wherein R is a C1 to C6 alkyl, C6 to C9 aryl or C7 to C10 aralkyl.

    摘要翻译: 提供了制备(R)-5- [2-(4-氟苯基)-5-(1-甲基乙基)-3-苯基-4 - [(苯基氨基)羰基] -1H-吡咯-1-基] -5-羟基-3-氧代-1-庚酸,R-取代的酯9,其包含:(a)使醛1与烯醇化形式的(S)-2-羟基-1,2,2-三苯基乙基乙酸酯取代基 在螯合助溶剂中; (b)(R,S)-5- [2-(4-氟苯基)-5-(1-甲基乙基)-3-苯基-4 - [(苯基氨基)羰基] -1H-吡咯-1-基 ] -3-羟基-1-戊酸,(S)-2-羟基-1,2,2-三苯基乙酯(2a和2b),使用碱,优选碱金属碱,优选在溶剂中形成羧酸 酸7; (c)用手性碱处理酸7以形成盐并纯化该盐以获得对映体富集的(R)-7手性碱盐; (d)(R)-7手性碱盐或衍生自(R)-7的游离碱的烷基化,形成(R)-5- [2-(4-氟苯基)-5-(1-甲基乙基) 3-苯基-4 - [(苯基氨基)羰基] -1H-吡咯-1-基] -5-羟基-3-氧代-1-庚酸,R-取代的酯9和阿托伐他汀钙6,其中R是C1 C6烷基,C6〜C9芳基或C7〜C10芳烷基。